<DOC>
	<DOCNO>NCT02762578</DOCNO>
	<brief_summary>This trial conduct Asia . The aim trial compare efficacy safety insulin degludec/insulin aspart BIAsp 30 subject type 2 diabetes .</brief_summary>
	<brief_title>Comparing Efficacy Safety Insulin Degludec/Insulin Aspart BIAsp 30 Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<criteria>Informed consent obtain trialrelated activity . Trialrelated activity procedure carry part trial , include activity determine suitability trial Male female least 18 year age Type 2 diabetes mellitus ( diagnose clinically ) least 6 month Insulin treat subject current treatment : basal insulin , premixed insulin selfmixed insulin regimen , administer daily ( OD ) BID without metformin . The treatment regimen remain unchanged least 8 week prior randomisation HbA1c 7.010.0 % ( inclusive ) central laboratory analysis Body mass index ( BMI ) equal 40.0 kg/m^2 Treatment sulphonylureas , meglitinides , DPP4 inhibitor , alphaglycosidase inhibitor within 8 week prior screen ( Visit 1 ) thiazolidinediones ( TZDs ) GLP1 receptor agonist within 12 week prior screen ( Visit 1 ) Anticipated change concomitant medication know interfere significantly glucose metabolism , systemic corticosteroid , betablockers monoamine oxidase ( MAO ) inhibitor Anticipated significant lifestyle change trial accord discretion investigator , e.g . shift work ( include permanent night/evening shift worker ) , well highly variable eat habit Cardiovascular disease , within last 6 month prior screen ( Visit 1 ) , define : stroke ; decompensated heart failure NYHA1 class III IV ; myocardial infarction ; unstable angina pectoris ; coronary arterial bypass graft angioplasty Any clinically significant disease disorder , except condition associate type 2 diabetes , investigator 's opinion could interfere result trial Previous participation trial . Participation define screen . Known suspected hypersensitivity trial product relate product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>